Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Approves Novartis Drug Glivec Label - Quick Facts

RELATED NEWS
Trade NVS now with 

Novartis AG (NVS: Quote) said the US Food and Drug Administration or FDA has approved an update to the Glivec label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors or GIST who met the risk of recurrence inclusion criteria of the pivotal trial. This treatment regimen improved recurrence-free survival or RFS and overall survival or OS for KIT+ GIST patients compared to 12 months of treatment.

The US approval was based on data from an international, multicenter, open-label, Phase III trial, with the study results demonstrating that 36 months of Glivec treatment significantly prolonged RFS compared to 12 months of Glivec treatment, which was a 54% reduction in the risk of recurrence. Moreover, 36 months of Glivec treatment resulted in a 55% reduction in the risk of death compared to one year of treatment.

Further to extending the Glivec label to three-year treatment duration in patients with KIT+ GIST after surgery, the FDA has agreed that all accelerated post-approval commitments for this indication have been met, confirming the clinical benefit of adjuvant treatment with Glivec.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Following the rally seen in the previous session, stocks may give back some ground in early trading on Friday. The major index futures are currently pointing to a lower open for the markets, with the Dow futures down by 38 points. The terrorist group known as the Islamic State in Iraq and the Levant (ISIL) is earning about $1 million each day by smuggling oil out of the Middle East, according to the US Treasury Department. Speaking at the Carnegie Endowment for International Peace on Thursday, Under Secretary for Terrorism and Financial Intelligence David Cohen said "ISIL has raised a significant amount of its money - many The U.K. economy grew at a slower pace in the third quarter in the face of rising uncertainty stemming from global economic conditions, preliminary estimates from the Office for National Statistics Office showed Friday. Gross domestic product climbed 0.7 percent from the second quarter, when it grew 0.9 percent.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.